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THICKENING of the most internal layer of the arterial 
walls in a human allograft (arterial intimal fihromu~­
dll;lr hyperplasia) was first reported in 1955 hy the pathol-
1I!!I't Gustav Dammin. in collaboration with Hume. I Since 
I';cn. many different terms have heen used to describe this 
l'llmplication of allogeneic kidney transplantation: obliter-
a\l\'c arteriopathy (OA). transplant atherosclerosis. trans-
plant arteriopathy. and others. In 1963. Porter et al~ linked 
Ihis complication to a genetic disparity hetween the recip-
Il'nl and the allograft. thus showing OA to be a specific 
suolype of rejection. widely known today as chronic rejec-
lion. 
Although OA is the principal manifestation of chronic 
rl'lcclion in all organ allografts. other accompanying fea-
IlIfl'S include interstitial and periarterial fibrosis and subse-
llll.:111 atrophy or loss of parenchymal cells:~ Chronic rejee-
i It'll of the liver. which is the focus of this presentation. has 
hC'c'n defined hy an international panel of experts. sane-
tllllled hy the World Congresses of Gastroenterology4 as: a 
" ... usually irreversible process characterized by two his-
topathologic features: obliterative vasculopathy and loss of 
oile ducts. Although these two components usually co-exist. 
they occasionally may occur independently. The process is 
elicited by a genetic disparity he tween the donor and the 
recipient. but other co-factors may he involved." 
FEATURES OF CHRONIC LIVER 
ALLOGRAFT REJECTION 
The arterial disease in liver allografts most commonly 
aneets medium and large-sized. first and second-order 
branches of the hepatic artery in the liver hilum.5- 1O The 
llIain feature is intimal thickening because of deposition of 
11l;lcrophage and/or myointimal cells that are often stuffed 
wilh lipids. combined with more modest myofibroblast 
proliferation and collagen deposition.3 Endothelial cell 
hypertrophy, transmural inflammation of varying severity. 
medial thinning. and inflammation and sclerosis of the 
adventitia also are frequently seen. The thickened intima 
may contain inflammatory cells, like T and B lymphocytes, 
macrophages. and occasionally. dendritic cells that signal 
the presence of an ongoing immune reaction.3 . 11 Eventu-
ally. the intimal thickening causes lumenal narrowing and 
diminished arterial blood flow to the dependent bile ducts. 
Small arterioles in the portal tracts are usually spared from 
Ihe intimal changes but may show medial hypertrophy 
;lIldor hyalinization. 
When the OA in large perihilar arteries is severe. small 
pUrial tract arteries. arterioles. and capillaries in the 
pnibiliary arterial plexus may be completely destroyed. 12· 13 
This results in compromised arterial flow to the dependent 
bile ducts. which can already be damaged or destroyed hy 
direct immunologic injuf)'. Moreover. progressive narrow-
ing of the lumen of larger arteries predisposes them to 
thromhosis. which in turn can cause necrosis and/or stric-
turing of large perihilar bile ducts. 
Damage and loss of small interlobular bile ducts is the 
second hallmark feature of chronic liver allograft rejec-
tion.,,-'u4-1" This manifestation is generally considered to 
be of secondary importance hecause isolated duct loss can 
occur for other reasons. such as obstructive cholangiopathy 
and adverse drug reactions. Bile ducts normally are present 
in 750i: to 800;' or more of portal tracts containing a hepatic 
arterial branch. Theoretically. duct loss could be considered 
to he present when more than 25% of the portal tracts are 
devoid of a bile ducl. Unfortunately. in routine clinical 
practice difficulty with reproducing bile duct and/or portal 
tract counts. and sampling problems associated with a small 
biopsy of a large organ. necessitates using a more conser-
vative figure of a 50% deficiency to be certain that there is 
ductopenia.4 
RISK FACTORS AND PATHOPHYSIOLOGIC 
MECHANISMS OF INJURY 
Risk factors identified by different groups for the develop-
ment of chronic rejection in the liver include multiple 
and/or poorly controlled acute cellular rejection episodes, 
chronic rejection in a previous failed allograft. a positive 
pre transplant Iymphocytotoxic crossmatch. anti-MHC anti-
bodies that develop after transplantation. cytomegalovirus 
(CMV) infection. matching at the class II MHC locus and 
mismatching at the MHC class ] locus. non-Caucasian 
recipient race. chronic hepatitis virus infection. and treat-
ment with a_interferon.6•7•11.l5.17-24 Hyperlipidemia. hyper-
tension. diabetes. and preservation injury have. to our 
knowledge. not been associated with chronic rejection of 
the liver, but are thought to contribute to the development 
of OA in other solid organ allografts. 
Several groups including ours have suggested that the 
pathogenic mechanisms involved in the development of OA 
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include a response to injury. the same hypothesis as that 
used to explain the development of atherosclerosis in the 
general population.J·II.13.:!5.~6 Thus. attempts at classifica-
tion are based on the nature of the initial insult. In an 
allograft. the cause of the injury appears to be primarily 
rooted in an allogeneic immune response. Likely arterial 
targets of this response include the endothelium. periarte-
rial dendritic cells, and lymphatic capillary endothelium in 
the adventitia: disruption of the lymphatics could cause 
arterial wall edema. However. multiple other co factors. 
including preservation injury, viral infections (especially 
CMV), hyperlipidemia. hypercholesterolemia, hyperten-
sion, and diabetes certainly could contribute to the insult 
and make worse the arterial disease. In any event. the 
arterial injury triggers a cascade of inflammation. growth 
and repair (explored in detail by Hayry and colleagues in 
this issue and elsewhere II) that eventually results in the 
characteristic OA described above. 
The second major target for injury in chronic rejection, 
the bile ducts, appears to be subjected to "double jeopar-
dy", 13.~fi They are susceptible to direct immunologic injury 
from invading inflammatory cells and indirectly to ischemic 
damage because of arterial occlusion and destruction of the 
peribiliary capillary plexus.I~.IJ.2fi Direct injury via cytotoxic 
T lymphocytes (CTI..) is usually noted histopathologically 
and is one of the defining features of both acute and chronic 
rejection. In addition. cytokines locally released by the 
invading lymphocytes can either directly injure the ducts or 
recruit neutrophils and macrophages via chemotaxins that 
indirectly cause damage through release of oxidative prod-
ucts. These same effector mechanisms can also destroy the 
small portal arterioles I J.~6 and fine webbing of capillaries I ~ 
that are the final conduit of arterial blood to the ducts. In 
addition, this unique portal microvasculature can be 
plugged and ruined by platelets and neutrophils in presen-
sitized patients. ;O.27.2H explaining the association between 
preformed antibodies and bile duct loss. 
Lastly. Donaldson et al 21 have suggested that bile ducts 
can also contribute to their own destruction by acting as 
antigen-presenting cells (APC) when their class II MHC 
antigens are matched with the recipient. In vitro. we have 
shown that such a process is possible1,!: however. the duct 
cells are much less efficient antigen presenters than are 
endothelial cells tested in the same assay. 
RESISTANCE OF THE LIVER ALLOGRAFT TO 
CHRONIC REJECTION 
Primary allograft survival for the first 2 to 3 years after 
transplantation usually is worse for liver than for heart or 
kidney allograft recipients. After this. the survival curves for 
primary liver allografts begin 10 Hatten out between 3 and 5 
years after transplantation whereas those for the heart and 
kidney show continual aurition. mostlv because of chronic 
rejection:1O This apparent difference i~ long-term allograft 
resistance to chronic rejection gleaned from survivall.:urves 
also surfaces at individual centers in studies of the struc-
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tural integrity and causes of late allograft dysfunction of 
liver vs other organs. 
Pappo et al;' 1 who studied the causes of liver allograft 
dysfunction in recipients who had survived for more than 5 
years with the same liver. showed that recurrent viral 
hepatitis is more often responsible for late liver allograft 
dysfunction than either acute or chronic (ductopenic) re-
jection.J1-J4 Obstructive cholangiopathy and recurrent al-
cohol are also surprisingly common.JI In all studies of 
long-term survivors,31-34 rejection (acute andlor chronic) is 
found in less than 25% of patients with biochemical evi-
dence of liver injury, and less frequently in asymptomatic 
patients with normal liver injury tests. 
Although these studies of long surviving recipients lend 
credence to the notion that a liver allograft is less suscep-
tible than kidney or heart allografts to chronic rejection, 
Wight et al (this issue) have offered the alternative expla-
nation that needle biopsy evaluation may underestimate the 
incidence of chronic rejection. This suggestion was not 
supported in a recent series of tolerance induction experi-
ments by Murase et al35 that focused on microchimerism in 
rats. Experimental evidence was provided showing that liver 
allografts are more resistant to chronic rejection than 
hearts. It was shown that a liver allograft can protect 
another solid organ from the same donor from chronic 
rejection. 3s In these experiments, a 2-week course of FK 
506 was able to induce acceptance for more than 100 days 
of a liver, heart. kidney, or bone marrow allograft. At first, 
these observations seemed an apparent contradiction to our 
recent hypothesis that microchimerism is a necessary pre-
condition for the evolution of donor-specific tolerance:'o-.w 
All of these drug-free animals accepted at 100 days a 
challenge heart allograft from the same donor with survival 
for 100 more days without regard for the kind of primary 
transplant. and with or without hematolymphoid chimerism 
detectable by immunocytochemistry. However. examination 
of the surviving challenge cardiac grafts 1U0 days posttrans-
plantation showed both multiple Quilty ksions~o and severe 
OA in the animals conditioned initially with a heart graft. In 
contrast. the challenge hearts in rats initially given a liver 
allograft of the same donor strain were completely pro-
tected from chronic rejection and had no Quilty lesions or 
OA. In these experiments. the presence of hematolymphoid 
microchimerism in the reCipient correlated with resistance 
to chronic rejection, although the study design precluded 
exclusion of a role for hepatic parenchymal cells:15 At the 
end. we also concluded that we had developed a useful 
experimental model with which to study chronic rejection in 
the challenge grafts without interference from immunosup-
pressive drugs. 
We helieve that protection from chronic rejection in this 
model is mediated by the multilineage donor hematolym-
phoid cells that emigrate from the liver and persist in small 
numbers in the recipient:'h .. \7 .. ",.4I.~~ In essence. the hypoth-
csis holds that a tiny fragment of the donor immune system. 
which is responsible for immunologic self-definition of the 











the recipient.~Q.4' If this is correct. one might expect that 
other properties of the donor immune system. such as 
resistance to autoimmunity. could be transferred to the 
recipient as previously shown for delayed-type hypersensi-
ti\itv reactions.~h 
riclaney et al44 recently tested this corollary hypothesis in 
liN rats which are susceptible to mercuric chloride-induced 
;Iuwimmunity. LEW rats. which are resistant to HgCI~­
Induced autoimmunity. were used as allogeneic bone mar-
row donors. In this BN model. rejection of the allogeneic 
bone marrow is prevented by a 2-week course of FK 506. 
Although all immunosuppression is then stopped. rare 
(...::: I :3.0(0) donor LEW hematolymphoid cells continue to 
survive in the BN recipients for more than 100 days. These 
microchimeric recipients become almost totally resistant to 
the development of autoimmunity from the HgCI~ injec-
tions.4~ 
These experimental observations may be relevant to the 
ohservation in long-term liver allograft survivors treated 
IlflL!inally for autoimmune chronic active hepatitis and 
f1f1marv biliarv cirrhosis (PBe) who have a low incidence 
.11lt! se~erity of recurrent disease.4h-~ I The potent immuno-
'"ppression required to prevent rejection has been used to 
c);plain these findings. but the same lack of recurrence has 
been noted in patients weaned from immunosuppression.52 
It may be that the immune stimulation and persistence of an 
integrated fragment of the donor's immune system analo-
gous to that in the rat experiments is the critical protective 
factor. 
The discovery that the development of sustained micro-
chimerism is an integral component of whole organ graft 
acccptance has opened many cryptic portals of transplan-
tation immunology and has provided a rational explanation 
for chronic rejection. This concept will allow new insights 
ahout chronic rejection to be developed and subjected to 
dir<.:ct experimentation. Our prediction is that immunobio-
IIl!.!lc manipulation of the recipient. such as the augmenta-
tlun hv donor bone marrow that currentlv is being evaluat-
nl" ciinically. will dispel the cloud of chr~nic reje~tion that 
11:IS for so long darkened the horizon for kidney and heart 
allograft recipients. 
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